The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).
 
Roy S. Herbst
Leadership - American Association for Cancer Research; IASLC; Immunocore; Junshi Pharmaceuticals; Society for Immunotherapy of Cancer; SWOG
Stock and Other Ownership Interests - Bolt Biotherapeutics; Checkpoint Therapeutics; Immunocore; Normunity
Consulting or Advisory Role - Abbvie; AstraZeneca; Bolt Biotherapeutics; Bristol-Myers Squibb; Candel Therapeutics; Checkpoint Therapeutics; Cybrexa Therapeutics; DynamiCure Biotechnology; eFFECTOR Therapeutics; EMD Serono; Genentech/Roche; Gilead/Forty Seven; HiberCell; I-Mab; Immune-Onc Therapeutics; Janssen; Johnson and Johnson; Junshi Pharmaceuticals; Lilly; Loxo; Merck; Mirati Therapeutics; NextCure; NextCure; Normunity; Novartis; Ocean Biomedical; OncoCyte; Oncternal Therapeutics; Pfizer; Refactor Health; Regeneron; Revelar; Ribon Therapeutics; Sanofi; Seagen; Xencor
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
Travel, Accommodations, Expenses - American Cancer Society; IASLC; SWOG
 
Masahiro Tsuboi
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi-Sankyo; Johnson & Johnson; Lilly Japan; Medtronic; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; AstraZeneca Japan; Chugai Pharma; MiRXES; MSD; Novartis
Research Funding - AstraZeneca Japan (Inst); BMG Inc (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb KK (Inst); Merck (Inst); MiRXES (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Tom John
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech
Consulting or Advisory Role - Amgen (Inst); AstraZeneca; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; Ignyta; Merck KGaA; MSD Oncology; Novartis; Pfizer; PharmaMar (Inst); Roche/Genentech; Specialised Therapeutics
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche; Roche
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Amgen; AstraZeneca; BeiGene; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Takeda
Consulting or Advisory Role - AstraZeneca; BeiGene; DaiichiSankyo; Janssen; Merck Serono; MSD; Novartis; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Haihe Biopharma (Inst); Lilly (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)
 
Margarita Majem
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Helsinn Therapeutics; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Roche
 
Christian Grohé
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Boehringer Ingelheim
Speakers' Bureau - Boehringer Ingelheim
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Jie Wang
No Relationships to Disclose
 
Jonathan W. Goldman
Consulting or Advisory Role - AbbVie; AstraZeneca; Bristol-Myers Squibb; Genentech; Lilly; Pfizer
Research Funding - Abbvie (Inst); Advaxis (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Shun Lu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; InventisBio Co. Ltd; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh Pharma; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Hansoh (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Lilly Suzhou Pharmaceutical Co. (Inst); Roche (Inst)
 
Wu-Chou Su
Consulting or Advisory Role - Bayer Schering Pharma; Lilly; Merck; MSD Oncology
 
Filippo de Marinis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Takeda
 
Frances A. Shepherd
Stock and Other Ownership Interests - AstraZeneca; Lilly
Honoraria - AstraZeneca; Daiichi Sankyo; Merck Serono; Takeda
Consulting or Advisory Role - AstraZeneca; Merck Serono
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Pfizer (Inst); Roche Canada (Inst)
 
Ki Hyeong Lee
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Pfizer
Research Funding - Merck
 
Nhieu Le
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb Belgium; Lilly O.; MSD
Research Funding - Merck
 
Arunee Dechaphunkul
No Relationships to Disclose
 
Dariusz M. Kowalski
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Johnson & Johnson/Janssen; Merck Serono; MSD; Pfizer; Roche/Genentech; Takeda
 
Lynne Poole
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; Lilly; Lilly (I); Takeda
Consulting or Advisory Role - Lilly (I)
 
Marta Stachowiak
Employment - AstraZeneca/MedImmune
 
Yuri Rukazenkov
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)